SEC Form 4 · accession 0000880771-16-000195
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wilson Wai-Shun Cheung
Officer — CFO & Senior VP, Finance
Period of report
Oct 17, 2016
Accepted (ET)
Oct 19, 2016 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 17, 2016 | M | 1,005 | $5.97 | A | 16,609 | D | |
| Common Stock | Oct 17, 2016 | S | 1,005 | $10.00 | D | 15,604 | D | |
| Common Stock | Oct 17, 2016 | S | 470 | $10.00 | D | 15,134 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F3 | $5.97 | Oct 17, 2016 | M | 1,005 | D | — | Aug 9, 2023 | Common Stock | 1,005 | 98,995 | D |
Explanation of responses
- F1The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2016.
- F2Granted under the Issuer's 2005 Equity Incentive Plan.
- F3Provided Reporting Person remains employed by Issuer, the options will vest based upon the successful and timely filing by the SEC filing dates of the 10-Q and 10-Ks for the period from September 30, 2013 through the end of 2014, with the last 10-K filed for the year ending December 31, 2014 by March 16, 2015 (the "Performance Target"). If the Performance Target is not achieved, the options will not vest and will expire on March 17, 2015.